Press release

06 Jul 2020  ·  Regulatory information

Guard Therapeutics appoints Peter Gilmour as Head of Preclinical Science

Guard Therapeutics has today announced that Peter Gilmour has been appointed Head of Preclinical Science. He has extensive experience in drug discovery and clinical drug development from leading positions at global pharmaceutical companies. Peter Gilmour will be part of the company’s management team and will take up his post on 1 August 2020.

Peter Gilmour, Ph.D., has a solid scientific background in experimental pharmacology, molecular biology and toxicology. He has a total of 25 years of experience in drug development from the global pharmaceutical companies Astellas and AstraZeneca. As project manager, he has participated in developing treatments in both cardiovascular, renal and respiratory diseases and has contributed to a number of approved patents.

“We are very happy and proud that Peter Gilmour has accepted the role of Head of Preclinical Science at Guard Therapeutics. His deep knowledge and experience from preclinical drug development in relevant therapeutic areas as well as project management at an international level will bring important new expertise to our company,” Tobias Agervald, CEO of Guard Therapeutics, says.

Peter Gilmour will contribute to the design and implementation of both preclinical studies and the ongoing clinical development programme for Guard Therapeutics’ investigational drug ROSgard, which is currently being evaluated in two phase 1 studies. If these studies produce positive results, a smaller study is then planned in the primary target group for treatment – patients undergoing cardiac surgery. This patient study is expected to be initiated in the final quarter of 2020.

”ROSgard has great potential to protect the kidneys from serious injury, including in patients undergoing heart surgery, and I look forward to contributing my knowledge to the continued development of this unique investigational drug,” Peter Gilmour, incoming Head of Preclinical Science at Guard Therapeutics, says.

All press releases